Vitamin K.

Vitamin D increases the body's output of calcium-binding proteins such as osteocalcin, which stay inactive until vitamin K carboxylates them. The two work in sequence, one making the proteins and the other switching them on, to support normal calcium handling in bone.

Vitamin K activates osteocalcin and matrix Gla protein, the proteins that bind calcium and help steer it into the bone matrix and away from soft tissue. When vitamin K is low these proteins stay uncarboxylated and calcium is directed less precisely.

At high supplemental doses vitamin E and its quinone metabolite interfere with vitamin K-dependent carboxylation, which can blunt vitamin K's support of normal blood clotting. This is a recognized reason to keep large vitamin E doses and vitamin K in balance rather than stacking them heavily.

Phylloquinone clears fast and is used mainly in liver, while menaquinones circulate longer and reach bone and vessel wall. Carrying both covers hepatic and peripheral carboxylation from the same vitamin K cycle.

Phylloquinone is the vitamer that dominates hepatic carboxylation of the clotting factors and is partly converted to MK-4 in tissue. It is the liver-side half of total vitamin K activity.

MK-7 stays in circulation for days rather than hours, so it reaches extrahepatic Gla proteins that phylloquinone largely misses. It extends the same carboxylation function to bone and vascular tissue.

Magnesium is the cofactor for the hydroxylases that make active vitamin D, and active vitamin D drives transcription of the Gla proteins vitamin K carboxylates. The two nutrients sit at different points on one calcium-handling sequence.

Vitamin D raises transcription of osteocalcin and matrix Gla protein and raises calcium absorption, while vitamin K performs the carboxylation that lets those proteins bind calcium. Neither step substitutes for the other.

Both phylloquinone and the menaquinones need bile salts and dietary fat for micellar uptake, so an oil carrier raises the absorbed fraction against a fasted dose. Vitamin K softgels are formulated in an oil base for this reason.

Phylloquinone and the menaquinones are lipophilic and are absorbed only after incorporation into mixed micelles, which requires bile salts and pancreatic lipase. When bile flow is low, fat-soluble vitamin uptake drops with it. Supplemental bile components are used in formulation for exactly this step, and the relationship is standard digestive physiology rather than a trial finding.

Vitamin K arrives in food dissolved in fat, and lipase must hydrolyse that fat before the vitamin can partition into a micelle. This is why vitamin K taken with a meal containing fat is absorbed more completely than on an empty stomach. The step is textbook digestion and applies to all four fat-soluble vitamins.

Blended enzyme products supply lipase alongside protease and amylase, and it is the lipase fraction that matters for vitamin K. The support is indirect: the enzymes act on the meal, not on the vitamin. Where fat digestion is already adequate, adding enzymes has no further absorption step to contribute.

Krill oil carries its fatty acids largely as phospholipids, which emulsify readily and form micelles without much bile input. Dissolving vitamin K in that matrix presents it to the intestine already dispersed. This is a delivery relationship, so it changes how much is absorbed rather than what the vitamin does once inside.

Lecithin phospholipids lower interfacial tension and help lipophilic actives disperse in aqueous gut contents. Vitamin K softgels commonly use a lecithin or oil base for this reason. The mechanism is physical dispersion. No chemical change to the vitamin occurs.

Phosphatidylcholine forms the mixed micelles that ferry fat-soluble vitamins to the enterocyte brush border. It is used both as an isolated excipient and as the active fraction of lecithin. As with any vehicle, it affects delivery and not the carboxylation chemistry downstream.

Menaquinone-7 and nattokinase are both products of Bacillus subtilis natto fermentation and often co-occur in a finished formula. Vitamin K supports the carboxylation of clotting factors, while nattokinase has fibrinolytic activity, so the two touch haemostasis from opposite ends. There is no combination trial establishing a net direction, and the honest description is that they are co-sourced rather than complementary.

Large alpha-tocopherol intakes have been documented to lower measures of vitamin K-dependent carboxylation, through competition for shared lipid transport and through tocopherol quinone metabolites that interfere with the vitamin K cycle. The interaction shows at supplemental amounts, not at food intakes. Where both are formulated together, the amounts and the timing matter.

Tocotrienols and the menaquinones both carry unsaturated isoprenoid side chains and travel in the same lipoprotein fractions after absorption. Competition for micellar space and for lipoprotein carriage is plausible on that basis. It is a mechanistic expectation from shared chemistry, not something measured in a human trial that has been located.

Retinol and vitamin K both need bile salt micelles to reach the enterocyte, and at high single doses the fat-soluble vitamins compete for that finite micellar capacity. In a mixed formula at ordinary amounts the competition is small. It becomes worth spacing doses only when one of them is supplied in a large isolated amount.

Beta-carotene is one of the most micelle-hungry dietary lipophiles and reduces the uptake of other fat-soluble compounds taken at the same time. Vitamin K sits in the same queue. This is an absorption interaction only. Neither affects the other's function once in circulation.

Colonic bacteria produce menaquinones ranging from MK-6 to MK-11, and some Lactobacillus and Bacillus species are documented menaquinone producers. How much of that bacterial pool is absorbed from the colon remains uncertain, since absorption there lacks bile. The relationship supports the body's own menaquinone supply and should be read as contributory, not as a substitute for dietary intake.

Bifidobacteria are part of the community whose metabolism shapes the colonic menaquinone pool, though the highest producers are Bacteroides and Escherichia species. Colonic absorption of these long-chain forms is limited and poorly quantified. The connection is real microbiology stated at its true confidence, not a claim that a probiotic supplies vitamin K.

The vitamin K cycle depends on reduction of the quinone to the hydroquinone form, work done by NAD(P)H-dependent reductases whose flavin cofactors derive from riboflavin. Riboflavin status therefore sits upstream of the reducing environment the vitamin K cycle needs. The link is biochemical and indirect. No clinical measurement of the pairing has been located.

Vitamin K carboxylates osteocalcin, the bone protein that binds calcium into the mineral matrix, while boron influences the handling of calcium and magnesium in bone. Both are supporting inputs to normal bone maintenance through different steps. The pairing rests on separate mechanisms rather than a tested combination.

Strontium is taken up into hydroxyapatite in place of some calcium, and carboxylated osteocalcin is the protein that binds calcium ions during that mineralisation. Because strontium alters the mineral phase itself, describing the pair as simply additive would overstate what is known. It is a modulating relationship at early confidence.